Patents by Inventor Florian Settele

Florian Settele has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Affinity ligands for the purification and detection of ubiquitin muteins
    Publication number: 20240309056
    Abstract: The present invention relates to novel affinity ligands for the affinity purification of ubiquitin muteins. In particular, the alkaline stable affinity ligands are useful for affinity chromatography purification and detection of a ubiquitin mutein (such as Affilin® protein). The novel affinity ligands for a ubiquitin mutein are based on artificial mosaic proteins of Protein A-like structure. The affinity ligands of the invention can be used for the purification and detection of ubiquitin muteins.
    Type: Application
    Filed: June 30, 2022
    Publication date: September 19, 2024
    Applicant: Navigo Proteins GmbH
    Inventors: Erik Fiedler, Mathias Kahl, Anja Katzchmann, Florian Settele
  • NOVEL PSMA SPECIFIC BINDING PROTEINS FOR CANCER DIAGNOSIS AND TREATMENT
    Publication number: 20220168386
    Abstract: The present invention relates to new binding proteins that are specific for prostate specific membrane antigen (PSMA). The invention further refers to PSMA binding proteins that further comprise a diagnostically or therapeutically active component. Further aspects of the invention cover the use of these PSMA binding proteins in medicine, for example, in diagnosis and therapy of cancer associated with PSMA expression.
    Type: Application
    Filed: April 8, 2020
    Publication date: June 2, 2022
    Applicant: Navigo Proteins GmbH
    Inventors: Eva Bosse-Doenecke, Manja Gloser-Bräunig, Florian Settele, Erik Fiedler, Ulrich Haupts
  • EGFR binding proteins
    Patent number: 10858405
    Abstract: The present invention relates to new EGFR binding molecules based on ubiquitin muteins (Affilin®), preferably Affilin molecules having a characteristic three amino acid residue motif. The invention further refers to EGFR binding molecules that bind to different or non-overlapping epitopes than the anti-EGFR monoclonal antibody Cetuximab. The invention further relates to the use of these EGFR binding proteins in medicine, preferably for use in the diagnosis or treatment of cancer.
    Type: Grant
    Filed: February 4, 2016
    Date of Patent: December 8, 2020
    Assignee: Navigo Proteins GmbH
    Inventors: Eva Bosse-Doenecke, Florian Settele, Erik Fiedler, Ulrich Haupts
  • NOVEL BINDING PROTEINS COMPRISING A UBIQUITIN MUTEIN AND ANTIBODIES OR ANTIBODY FRAGMENTS
    Publication number: 20190292266
    Abstract: The present invention relates novel binding molecules comprising a ubiquitin mutein (AFFILIN®) and a monoclonal antibody or antibody fragment. The invention refers to bispecific and/or bivalent binding proteins or to a therapeutically or diagnostically active component. The invention further relates to the use of these binding proteins in medicine, preferably for use in the treatment of cancer or autoimmune disorders.
    Type: Application
    Filed: April 5, 2019
    Publication date: September 26, 2019
    Applicant: Navigo Proteins GmbH
    Inventors: Eva Bosse-Doenecke, Mathias Kahl, Florian Settele, Paul Knick, Markus Liebscher, Erik Fiedler, Julia Hennicke
  • HER2 BINDING PROTEINS BASED ON DI-UBIQUITIN MUTEINS
    Publication number: 20180273636
    Abstract: The present invention relates to new Her2 binding molecules based on di-ubiquitin muteins. The invention further refers to Her2 binding proteins optionally fused or conjugated to a moiety modulating pharmacokinetics or to a therapeutically or diagnostically active component. The invention further relates to the use of these Her2 binding proteins in medicine, preferably for use in the diagnosis or treatment of cancer.
    Type: Application
    Filed: July 19, 2016
    Publication date: September 27, 2018
    Applicant: Navigo Proteins GmbH
    Inventors: Florian Settele, Madlen Zwarg, Manja Gloser, Eva Bosse-Doenecke, Erik Fiedler, Ulrich Haupts
  • NOVEL EGFR BINDING PROTEINS
    Publication number: 20180030098
    Abstract: The present invention relates to new EGFR binding molecules based on ubiquitin muteins (Affilin®), preferably Affilin molecules having a characteristic three amino acid residue motif. The invention further refers to EGFR binding molecules that bind to different or non-overlapping epitopes than the anti-EGFR monoclonal antibody Cetuximab. The invention further relates to the use of these EGFR binding proteins in medicine, preferably for use in the diagnosis or treatment of cancer.
    Type: Application
    Filed: February 4, 2016
    Publication date: February 1, 2018
    Applicant: Navigo Proteins GmbH
    Inventors: Eva Bosse-Doenecke, Florian Settele, Erik Fiedler, Ulrich Haupts
  • NOVEL BINDING PROTEINS COMPRISING A UBIQUITIN MUTEIN AND ANTIBODIES OR ANTIBODY FRAGMENTS
    Publication number: 20180030140
    Abstract: The present invention relates novel binding molecules comprising a ubiquitin mutein (Affilin®) and a monoclonal antibody or antibody fragment. The invention refers to bispecific and/or bivalent binding proteins or to a therapeutically or diagnostically active component. The invention further relates to the use of these binding proteins' medicine, preferably for use in the treatment of cancer or autoimmune disorders.
    Type: Application
    Filed: February 4, 2016
    Publication date: February 1, 2018
    Applicant: Navigo Proteins GmbH
    Inventors: Eva Bosse-Doenecke, Mathias Kahl, Florian Settele, Paul Knick, Markus Liebscher, Erik Fiedler, Julia Hennicke